Novo Holdings participates in €23 million Series A for Tribune Therapeutics to advance next-generation anti-fibrotic therapies

Whats Happening:

Novo Holdings is participating in a €23 million Series A funding round for Tribune Therapeutics. The round was led by LifeArc Ventures and joined by other investors. Tribune Therapeutics is developing disease-modifying therapies for fibrotic conditions, with their lead program TRX-44 targeting idiopathic pulmonary fibrosis (IPF).

Key Moves:

• Novo Holdings participates in €23 million Series A for Tribune Therapeutics

• Funding will support advancement of CCN family inhibitor TRX-44 into clinical trials

• Tribune Therapeutics was co-founded by Novo Holdings and HealthCap in 2020

By The Numbers:

• €23 million Series A funding round

• Novo Holdings had total assets of EUR 149 billion as of year-end 2023

• Tribune Therapeutics was founded in 2020

Key Quotes:

• "Tribune's scientific founders have discovered key insights into the mechanism of action of CCNs, leading to an elegant and powerful approach to harness the biology of CCNs to shut down a key pro-fibrotic pathway." - João Ribas, PhD, Principal of Novo Holdings

• "Tribune's foundational science has far-reaching therapeutic potential, and Novo Holdings has been a great partner in bringing the company to fruition through its early support and extended network." - Georg Vo Beiske, PharmD, Tribune Chief Executive Officer

Bottom Line:

Novo Holdings' participation in Tribune Therapeutics' Series A funding round demonstrates its commitment to advancing innovative therapies for fibrotic diseases. This investment aligns with Novo Holdings' mission to improve people's health and supports the development of potentially groundbreaking treatments for conditions like idiopathic pulmonary fibrosis.

Read Full Article